NANO Stock Analysis: Nanobiotix S.A | PA
Biotechnology | PA, France | Market Cap: 1.689m EUR | 12M Return: 695.7% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 3.71M
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Nanobiotix S.A. is a French clinical-stage biotechnology company developing nanoparticle-based therapies, with a primary focus on oncology and other areas of unmet medical need. Its lead asset, NBTXR3, is a suspension of crystalline hafnium oxide nanoparticles designed to enhance the effects of radiotherapy, and is being investigated across multiple solid tumor indications, including soft tissue sarcoma, head and neck cancer, and cancers of the liver, prostate, pancreas, esophagus, rectum, and lung. The company has out-licensed development and commercialization rights for NBTXR3 in China, South Korea, Singapore, and Thailand to Lian Oncology Limited. As a clinical-stage biotech, Nanobiotix has no marketed products and its value proposition rests on the progression of its pipeline and the validation provided by strategic regional partnerships.
- NBTXR3 Phase III head and neck cancer data readout approaches
- Lian Oncology partnership advances Asia Pacific NBTXR3 commercialization
- Operating cash burn raises equity dilution and financing risk
| Net Income: -24.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.29 > 0.02 and ΔFCF/TA 64.80 > 1.0 |
| NWC/Revenue: 17.69% < 20% (prev -21.80%; Δ 39.49% < -1%) |
| CFO/TA -0.49 > 3% & CFO -33.4m > Net Income -24.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.09 > 1.5 & < 3 |
| Outstanding Shares: last quarter (47.4m) vs 12m ago 22.15% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 43.86% > 50% (prev -17.22%; Δ 61.08% > 0%) |
| Interest Coverage Ratio: -1.30 > 6 (EBIT TTM -13.6m / Interest Expense TTM 10.4m) |
| A: 0.08 (Total Current Assets 62.8m - Total Current Liabilities 57.5m) / Total Assets 67.8m |
| B: -0.35 (Retained Earnings -24.0m / Total Assets 67.8m) |
| C: -0.20 (EBIT TTM -13.6m / Avg Total Assets 67.6m) |
| D: -0.55 (Book Value of Equity -84.5m / Total Liabilities 152.2m) |
| Altman-Z'' = -2.58 = D |
As of July 08, 2026, the stock is trading at EUR 33.10 with a total of 188,643 shares traded. Over the past week, the price has changed by +3.12%, over one month by +7.68%, over three months by +29.20% and over the past year by +695.67%.
Current recommended Stop Loss: 30.40 (which is 8.2% or 1.3 ATR below the current price).
Nanobiotix S.A has no consensus analysts rating.
P/E Forward = 104.1667
P/S = 51.8251
P/B = 61.9864
Revenue TTM = 29.6m EUR
EBIT TTM = -13.6m EUR
EBITDA TTM = -12.1m EUR
Long Term Debt = 89.1m EUR (from longTermDebt, last quarter)
Short Term Debt = 4.31m EUR (from shortTermDebt, last quarter)
Debt = 98.4m EUR (from shortLongTermDebtTotal, last quarter) + Leases 3.10m
Net Debt = 87.6m EUR (calculated: Debt 98.4m - CCE 10.8m)
Enterprise Value = 1.78b EUR (1.69b + Debt 98.4m - CCE 10.8m)
Interest Coverage Ratio = -1.30 (Ebit TTM -13.6m / Interest Expense TTM 10.4m)
EV/FCF = -91.24x (Enterprise Value 1.78b / FCF TTM -19.5m)
FCF Yield = -1.10% (FCF TTM -19.5m / Enterprise Value 1.78b)
FCF Margin = -65.69% (FCF TTM -19.5m / Revenue TTM 29.6m)
Net Margin = -80.83% (Net Income TTM -24.0m / Revenue TTM 29.6m)
Gross Margin = unknown ((Revenue TTM 29.6m - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 26.22 (Enterprise Value 1.78b / Total Assets 67.8m)
Interest Expense / Debt = 10.56% (Interest Expense 10.4m / Debt 98.4m)
Taxrate = 25.0% (non-US conservative default 25%)
NOPAT = -10.2m (EBIT -13.6m * (1 - 25.00%)) [loss with tax shield]
Current Ratio = 0.98 (Total Current Assets 62.8m / Total Current Liabilities 64.1m)
Debt / Equity = -1.16 (negative equity) (Debt 98.4m / totalStockholderEquity, last quarter -84.5m)
Debt / EBITDA = -7.26 (negative EBITDA) (Net Debt 87.6m / EBITDA -12.1m)
Debt / FCF = -4.50 (negative FCF - burning cash) (Net Debt 87.6m / FCF TTM -19.5m)
Total Stockholder Equity = -60.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -35.45% (Net Income -24.0m / Total Assets 67.8m)
RoE = 39.78% (negative equity) (Net Income TTM -24.0m / Total Stockholder Equity -60.2m)
RoCE = -46.94% (EBIT -13.6m / Capital Employed (Equity -60.2m + L.T.Debt 89.1m))
RoIC = -77.77% (negative operating profit) (NOPAT -10.2m / Invested Capital 13.1m)
WACC = 8.26% (E(1.69b)/V(1.79b) * Re(8.28%) + D(98.4m)/V(1.79b) * Rd(10.56%) * (1-Tc(0.25)))
Discount Rate = 8.28% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 98.88 | Cagr: 15.01%
[DCF] Fair Price = unknown (Cash Flow -19.5m)
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: -1.73 | # QB: -1
EPS current Year (2025-12-31): EPS=-0.07 | Chg30d=+7.14% | Revisions=+25% | GrowthEPS=+95.5% | GrowthRev=+881.6%
EPS next Year (2026-12-31): EPS=-0.30 | Chg30d=-250.00% | Revisions=+17% | GrowthEPS=+40.5% | GrowthRev=+34.5%
[Analyst] Revisions Ratio: +29% (up=3, down=1)